[Impact of a coordinated regional organization to secure the management of patients on oral anticancer drugs: CHIMORAL, a comparative trial].

DISCUSSION: This model does not show any difference on the primary endpoint. The lack of randomization, patient selection, power loss, and local initiatives to monitor these patients may have biased the analysis. A large number of uses of the healthcare system were observed. These results confirm the need for a dedicated care pathway for the patient with oral anticancer drugs.
PMID: 31130274 [PubMed - as supplied by publisher]

Source: Bulletin du Cancer - May 22, 2019 Category: Cancer & Oncology Authors: Maritaz C, Gault N, Roy C, Tubach F, Burnel S, Lotz JP, CHIMORAL Tags: Bull Cancer Source Type: research